In honor of American Heart Month, Healio Dermatology interviewed experts and explored the connection between skin disease and heart health.The discovery of this relationship can be traced back to ...

Many patients with overweight or obesity discontinue glucagon-like peptide-1 receptor agonist therapy within one year.

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

A new clinical trial showed promising results in curbing alcohol cravings in individuals with moderate alcohol-use disorder.

ORLANDO, FLA. — Increasing levels of protein and fiber, stressing portion control, and adding savory flavors are ways that ...

Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...

A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and ...

A doctor emphasized that ozempic, a lab-engineered drug, effectively activates GLP-1 receptors for weight loss, unlike foods ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.